JP2023516284A - カンナビジオールの組成物および治療的使用 - Google Patents

カンナビジオールの組成物および治療的使用 Download PDF

Info

Publication number
JP2023516284A
JP2023516284A JP2022550009A JP2022550009A JP2023516284A JP 2023516284 A JP2023516284 A JP 2023516284A JP 2022550009 A JP2022550009 A JP 2022550009A JP 2022550009 A JP2022550009 A JP 2022550009A JP 2023516284 A JP2023516284 A JP 2023516284A
Authority
JP
Japan
Prior art keywords
cannabidiol
pharmaceutical composition
gating
syndrome
heart disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550009A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021165992A5 (https=
JP2023516284A5 (https=
Inventor
パテル，マニット
チャールズ ルーベン，ピーター
アミン フーダ，モハメド
ゴーバンルー，モハマド－レザ
アナント ジャダブ，ビシャル
エイ ペイジ，ダナ
チョウダリー，カウシク
ラッダ，ルシノバ
ファテルペカル，テジャス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MERCHANT, Shreema
Original Assignee
MERCHANT, Shreema
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MERCHANT, Shreema filed Critical MERCHANT, Shreema
Publication of JP2023516284A publication Critical patent/JP2023516284A/ja
Publication of JPWO2021165992A5 publication Critical patent/JPWO2021165992A5/ja
Publication of JP2023516284A5 publication Critical patent/JP2023516284A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022550009A 2020-02-19 2021-02-19 カンナビジオールの組成物および治療的使用 Pending JP2023516284A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202021007184 2020-02-19
IN202021007184 2020-02-19
IN202021013770 2020-03-29
IN202021013770 2020-03-29
PCT/IN2021/050159 WO2021165992A1 (en) 2020-02-19 2021-02-19 Compositions and therapeutic uses of cannabidiol

Publications (3)

Publication Number Publication Date
JP2023516284A true JP2023516284A (ja) 2023-04-19
JPWO2021165992A5 JPWO2021165992A5 (https=) 2024-07-09
JP2023516284A5 JP2023516284A5 (https=) 2024-07-09

Family

ID=77391770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550009A Pending JP2023516284A (ja) 2020-02-19 2021-02-19 カンナビジオールの組成物および治療的使用

Country Status (9)

Country Link
US (1) US20230123654A1 (https=)
EP (1) EP4106870A4 (https=)
JP (1) JP2023516284A (https=)
CN (1) CN115916336A (https=)
AU (1) AU2021223191A1 (https=)
CA (1) CA3171890A1 (https=)
IL (1) IL295753A (https=)
WO (1) WO2021165992A1 (https=)
ZA (1) ZA202210355B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296892A (en) * 2020-03-29 2022-12-01 Akseera Pharma Corp Interaction of sars-cov-2 proteins through a molecular or cellular mechanism of host cells and compounds for the treatment of covid -19
AU2021250462A1 (en) * 2020-04-02 2022-12-01 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
WO2022122904A1 (en) * 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
JPWO2024043242A1 (https=) * 2022-08-23 2024-02-29

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512564A (ja) * 2013-03-13 2016-04-28 ユニバーシティ・オブ・シンシナティ Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087374B2 (en) * 2003-06-26 2006-08-08 The Research Foundation Of State University Of New York Screen for sodium channel modulators
WO2016161138A1 (en) * 2015-03-31 2016-10-06 Stamets Paul Edward Antiviral activity from medicinal mushrooms and their active constituents
LT6486B (lt) * 2016-04-13 2018-01-10 UAB "SatiMed" Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
IL262713B2 (en) * 2016-05-02 2024-07-01 Stero Biotechs Ltd Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases
CN108079305A (zh) * 2016-11-23 2018-05-29 汉义生物科技（北京）有限公司 大麻二酚与三环类抗抑郁药的药物组合物及其用途
AU2018273410A1 (en) * 2017-05-26 2020-01-16 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
US20210085801A1 (en) * 2017-12-12 2021-03-25 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
KR102632946B1 (ko) * 2018-01-13 2024-02-05 트루티바 인코포레이티드 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 大麻二酚组合物及其用途
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512564A (ja) * 2013-03-13 2016-04-28 ユニバーシティ・オブ・シンシナティ Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ACTA PHARMACOLOGICA SINICA, vol. 36, JPN6025001140, 2015, pages 454 - 462, ISSN: 0005641513 *
BIOPHYSICAL JOURNAL, vol. Vol.118, Issue.3, Suppl.1, JPN6025001146, 7 February 2020 (2020-02-07), pages 2825 - 578, ISSN: 0005641507 *
BRITISH JOURNAL OF PHARMACOLOGY (2014), vol. 171, JPN6025001141, 2014, pages 427 - 437, ISSN: 0005641512 *
BRITISH JOURNAL OF PHARMACOLOGY, vol. 160, JPN6025001145, 2010, pages 1234 - 1242, ISSN: 0005641508 *
CIRC ARRHYTHM ELECTROPHYSIOL, vol. Vol.10:e003560, JPN6025001142, 2017, pages 1 - 12, ISSN: 0005641511 *
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 20, no. 1, JPN6025001144, 2015, pages 76 - 83, ISSN: 0005641509 *
PHARMACOLOGY & THERAPEUTICS, vol. 175, JPN6025001143, 2017, pages 133 - 150, ISSN: 0005641510 *

Also Published As

Publication number Publication date
AU2021223191A1 (en) 2022-10-13
CN115916336A (zh) 2023-04-04
IL295753A (en) 2022-10-01
US20230123654A1 (en) 2023-04-20
WO2021165992A1 (en) 2021-08-26
EP4106870A4 (en) 2024-04-10
EP4106870A1 (en) 2022-12-28
CA3171890A1 (en) 2021-08-26
ZA202210355B (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP2023516284A (ja) カンナビジオールの組成物および治療的使用
JP6570597B2 (ja) 新規方法
US8802702B2 (en) Compounds for reducing drug resistance and uses thereof
EP3344296B1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
JP2017537129A (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
US11071731B2 (en) Allosteric modulators of the mu opioid receptor
WO2024145719A1 (en) Improved pharmacokinetics of tryptamine prodrugs
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
WO2019094434A1 (en) Therapeutic combination for treatment of cerebellar ataxia
KR20240012533A (ko) 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도
WO2025031474A1 (en) Method and medicament for treating endometriosis
HK40077420A (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
WO2022247834A1 (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
Castaño Aniceto Design and evaluation of ophthalmic formulations in an unlicensed medicines manufacturing unit
HK40023859A (en) Targeted therapeutics
NZ714294A (en) Methods and compositions for treating depression using cyclobenzaprine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240216

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250715